Routine SEBI compliance certificate filed for Q2 FY26

Compliance View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.7%Next day

₹75.00

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.0%+3.6% vs market

Pharmaceuticals peers, median of 173sector-0.8%+3.5% vs sector

By the next day the stock moved 3.6 pts more than Nifty Microcap 250 and 3.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

—+0.7—+0.0—

Next day

+2.7-1.0+3.6-0.8+3.5

-3.1-0.3-2.8-0.6-2.5

+3.7-1.9+5.6-1.9+5.6

+0.0-4.5+4.5-3.5+3.5

-3.0-5.5+2.5-4.4+1.4

-5.3-7.3+1.9-4.3-1.0

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ishita Drugs submitted a routine compliance certificate to BSE for the quarter ended 30 September 2026. The certificate, issued by their Registrar and Share Transfer Agent Bigshare Services, confirms that all dematerialization requests received from depository participants were processed and the underlying securities were listed on the stock exchange within the required 15 days. This is a standard quarterly filing required under SEBI Regulation 74(5).

Likely market impact

Standard regulatory compliance filing with no material business or price impact for shareholders.